In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Insmed (INSM – Research Report), with a price target of $98.00.
In a note early Tuesday, TD Cowen analyst Ritu Baral said that the outcome of the brensocatib trial at both dosage levels was ...
TD Cowen analyst Ritu Baral reiterated a Buy rating on Vera Therapeutics (VERA – Research Report) yesterday and set a price target of $60.00. The company’s shares closed last Friday at $27.46.
Distributor relationships are being explored in the Middle East and North Africa. Ritu Baral, Analyst, TD Cowen: We’re going to go ahead and get started. Thank you very much for joining us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results